1.	A Study of PD-0332991 + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A5481008, NCT01740427
2.	PD 0332991 in Treating Patients With Refractory Solid Tumors Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UPCC 03909, NCI-2009-01467, NCT01037790
3.	PD0332991 in Patients With Advanced or Metastatic Liposarcoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 10-094, NCT01209598
4.	A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 10105, NCT01227434
5.	Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC. Phase: Phase II Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: PD0332991, NCT01291017
6.	A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11D.14, 2010-41, NCT01356628
7.	A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11-003234, NCT01536743
8.	Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: OOTR-N007/LET-CDK, NCT01709370
9.	PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: 201301106, NCT01723774
10.	Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 0903010300, NCT01111188
11.	PD0332991/Paclitaxel in Advanced Breast Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UPCC 02111, NCT01320592
12.	PD-0332991, 5-FU, and Oxaliplatin for Advanced Colorectal Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2011-219, WS1877559, NCT01522989
13.	A Study Of PD-0332991 (Cyclin Dependent Kinase 4/6 Inhibitor) In Japanese Patients With Advanced Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A5481010, NCT01684215
14.	A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: J1275, NA_00076003, NCT01701375